Posts by: David Melamed, PhD

David Melamed, PhD

David holds a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. As a Graduate Student and Postdoctoral Fellow at Columbia, his work helped redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

October 12, 2020October 12, 2020

TXNIP Protein Deficiency Linked to Poor Prognosis for AML Patients, Study Finds

News

Low expression levels of the protein TXNIP — thioredoxin interacting protein — was associated with worse outcomes in people with acute myeloid leukemia (AML), according to the results of a ... Read more

October 1, 2020October 1, 2020

‘Find the Right Fit’ Aims to Educate, Support People With Secondary AML

News

Jazz Pharmaceuticals, with help from the Myelodysplastic Syndrome (MDS) Foundation and the Cancer Support Community, has launched Find the Right Fit, an initiative providing educational resources about MDS and secondary ... Read more

July 16, 2020July 16, 2020

First Patient Dosed in Phase 1 Trial Testing Small Molecule Treatment CA-4948 for AML

News

The first patient has been dosed in a Phase 1 trial investigating the small molecule CA-4948 as a treatment for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes ... Read more

February 28, 2020March 5, 2020

Medigene’s AML Cancer Vaccine Shows Positive Results in Clinical Trial

News

A completed Phase 1/2 clinical trial has shown encouraging results for Medigene‘s immune cell vaccine — which uses dendritic cells to “educate” T-cells about their targets — in people with ... Read more

February 14, 2020February 26, 2020

First Patient Dosed in Phase 2 Trial of Alvocidib for Relapsed or Refractory AML, Tolero Says

News

The first patient has been dosed in a Phase 2 clinical trial examining Tolero Pharmaceuticals‘ investigational CDK9 inhibitor alvocidib as treatment for people with acute myeloid leukemia (AML) who failed ... Read more

January 9, 2020February 6, 2020

Sellas Begins Screening AML Patients for Phase 3 Trial Testing Cancer Vaccine Galinpepimut-S

News

Sellas Life Sciences has started screening acute myeloid leukemia (AML) patients for a Phase 3 clinical trial evaluating its experimental vaccine galinpepimut-S (GPS) as a second-line maintenance therapy for patients who ... Read more